YD Bio Ltd (YDES) Financiero

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The company is headquartered in Taipei City, Taipei. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.